ReviewF1000Research2020
The most recent advances in understanding and managing hidradenitis suppurativa.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- International Expert Consensus on Knowledge Gaps in Care for Dermatologic Disorders in Skin of Color.International journal of dermatology · 2026Article
- Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association.JAAD case reports · 2025Article
- Demographic Data, Risk Factors, and Disease Burden of HS Patients in Lithuania at a Reference Center.Healthcare (Basel, Switzerland) · 2024Article
- Improving hidradenitis suppurativa management: consensus statements from physicians and patients' perspectives.Archives of dermatological research · 2024Review
- Multiple verrucous squamous cell carcinomas developing on chronic hidradenitis suppurativa lesions-a rare case report from Romania.Frontiers in medicine · 2024Article
- Upregulation of Caveolae-Associated Proteins in Lesional Samples of Hidradenitis Suppurativa: A Case Series Study.JID innovations : skin science from molecules to population health · 2023Article
- Hidradenitis suppurativa and squamous cell carcinoma: a systematic review of the literature.Postepy dermatologii i alergologii · 2023Review
- Hidradenitis Suppurativa and Five Key Vitamins and Minerals.Skin appendage disorders · 2023Review
- Article
- Reconstruction of the Axillary Region after Excision of Hidradenitis Suppurativa: A Systematic Review.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2023Review
- Adiponectin Contributes to the Inflammatory Milieu in Hidradenitis Suppurativa.Dermatology practical & conceptual · 2022Article
- Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages.The Journal of investigative dermatology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.